What Researchers Did
Researchers conducted a systematic literature review to discuss the use of hyperbaric oxygen therapy (HBOT) as an adjuvant treatment.
What They Found
The review reiterated that HBOT remains the gold standard for conditions like air or gas embolism and decompression illness. However, its value as an adjuvant therapy for other indications, such as carbon monoxide poisoning or clostridial necrosis, was found to be less clear, highlighting problems in assessing its efficacy using evidence-based medicine criteria.
What This Means for Canadian Patients
Canadian patients considering hyperbaric oxygen therapy as an adjuvant treatment should discuss the specific evidence for their condition with their healthcare provider. The effectiveness of HBOT varies significantly depending on the indication, and its role in many adjuvant settings requires further clarification.
Canadian Relevance
This study does not have a direct Canadian connection.
Study Limitations
A key limitation identified was the difficulty in assessing the true value of hyperbaric oxygen therapy using strict evidence-based medicine criteria.